History and Heritage

Innovation Timeline

Discover our rich history of innovation and commitment to the science of laboratory diagnostics.

1972

  • Abbott launches its first hepatitis test.
  • Abbott introduces ABA-100 blood chemistry analyzer to determine enzyme levels and analyze blood components.

1974

  • Abbott launches a non-radioactive hepatitis screening test called Auscell.
  • Abbott introduces Ausria II, an improved hepatitis test that allows hospitals and blood banks, for the first time, to supply blood for transfusion the same day it is drawn.

1978

  • Abbott introduces a commercial product for the diagnosis of hepatitis A.

1979

  • Quantum, an automated immunoassay system employing a new enzyme immunoassay (EIA) technology is introduced. Quantum enabled Abbott to convert its hepatitis product line from radioactive tests to enzyme immunoassays.

1981

  • Introduced therapeutic drug monitoring system, (TDx).

1985

  • Abbott receives FDA approval of the first licensed antibody test to identify HIV virus in blood, helping to secure the safety of the blood supply. This is one of our greatest achievements and the first significant medical victory against what had, until then, seemed an unstoppable threat.

1986

  • Abbott develops TestPack, a self-contained diagnostic test that allows doctors to perform blood-sophisticated immunoassay tests while the patient is in the office.

1987

  • Abbott introduces IMx, a bench-top immunoassay system.

1991

  • Abbott develops an automated test for monitoring prostate specific antigen (PSA).

1992

  • Abbott enters the hematology market with the acquisition of Sequoia Turner Corporation.

1994

  • Abbott launches AxSYM which combines immunoassay technologies employed in the IMx and TDx systems.
  • Abbott introduces the Global Surveillance Program to detect and monitor emerging HIV and hepatitis strains around the world.

1995

  • Abbott develops ABBOTT PRISM the first fully automated, high-volume blood screening platform.

1997

  • Abbott launches a combination test for HTLV-I and HTLV-II.

1998

  • Abbott launches a large number of new systems, including Alcyon and Aeroset, two clinical chemistry analyzers, and Determine, a line of self-performing assays. The company also broadens its product offering with the acquisition of International Murex Technologies Corp., adding microtiter-based immunoassays and microbiology products.

1999

  • Abbott introduces the ARCHITECT i2000, the first in a planned series of analyzers for the clinical laboratory.

2001

  • Abbott acquires Vysis, Inc, a leading genomic diagnostics company that develops and markets clinical laboratory products, which provide information critical to the evaluation and management of cancer, prenatal disorders and other genetic diseases.

2004

  • As a part of the Global Surveillance Program, Abbott identifies and characterizes a rare Group N virus — only 1 of only 2 institutions in the world to have done so.

2005

  • The ABBOTT PRISM, high-volume blood bank screening platform is launched in the U.S.
  • Manufacturing capacity is expanded at several European locations, including Dartford, England, Sligo and Longford, Ireland, and Wiesbaden, Germany. The new and expanded sites help Abbott meet the increasing global demand for diagnostic testing in areas such as infectious diseases, cancer, thyroid and cardiovascular.
  • CELL-DYN Sapphire, an automated, high-volume hematology instrument, is introduced.

2006

  • Abbott launches the automated, mid-volume analyzer CELL-DYN RUBY hematology instrument.
  • Abbott receives approval for a test for Hepatitis B surface antigen for its ABBOTT PRISM system.
  • Abbott introduces Labs Are Vital, a multi-year global program designed to strengthen the role of the clinical laboratory and its professionals. Numerous professional associations align with Labs Are Vital, including the International Federation of Clinical Chemistry and Laboratory Medicine.

2007

  • Abbott receives approval for the ARCHITECT CORE-M (anti-HBc IgM) assay.
  • Abbott launches ARCHITECT c16000 and ARCHITECT ci16200 to expand Abbott's premier immunoassay and clinical chemistry platform for large-volume needs.
  • Abbott receives approval for its automated Hepatitis B test for use on ARCHITECT immunoassay analyzers.

2008

  • Abbott launches the ARCHITECT i1000SR immunochemistry analyzer, expanding its ARCHITECT family of diagnostics instrument systems for clinical laboratories.
  • Abbott receives approval of a test for HTLV-I/HTLV-II for use on the ABBOTT PRISM instrument.

2009

  • Abbott receives CE Mark (Conformite Europeene) for the ARCHITECT NGAL assay.
  • Abbott receives approval for the Abbott Prism HIV O Plus assay.
  • Abbott partners with the University of California in San Francisco to form the UCSF-Abbott Viral Diagnostics and Discovery Center, which uses deep sequencing and ultra-rapid pathogen identification technologies to identify and characterize novel human viruses.

2010

  • Abbott receives approval for first U.S.-approved HIV Combo test, the ARCHITECT HIV Ag/Ab Combo Assay, to detect virus earlier.
  • Abbott receives clearance for the ARCHITECT HE4 Assay.
  • Abbott receives approval for the ABBOTT PRISM Chagas test.
  • Abbott celebrates 25 years of HIV diagnostics.

2011

  • Abbott receives clearance for the ARCHITECT 25-OH Vitamin D assay.

2012

  • Abbott introduces OneLab, an integrated web-based software platform to manage laboratory information.

2013

  • Abbott launches ARCHITECT STAT High Sensitive Troponin-I (hsTnI) to aid doctors in evaluating potential heart attacks.
  • Abbott globally launches the ACCELERATOR a3600, a next generation automation solution, to help laboratories address the need to process tests faster while handling increased volume.

2014

  • Abbott announces its innovative diagnostic platform, known as IRIDICA. IRIDICA uses a combination of sophisticated testing technologies known as Polymerase Chain Reaction/Electrospray Ionization Mass Spectrometry (PCR/ESI-MS) to rapidly identify infection-causing pathogens directly from a patient's sample, without the need for culture.

2015

  • Abbott Virus Hunters discover a new strain of Human Pegivirus, 2 (HPgV-2).
  • Abbott becomes a strategic partner in Georgian HCV Elimination program.

2016

  • Abbott launches the first systems in its Alinity series, a family of diagnostics and informatics systems that represent a major leap forward in terms of reliability, cost, capacity, space efficiency, and ease of use.
  • Research conducted at Emory University shows that Abbott's ARCHITECT STAT High Sensitive Troponin-I (hsTnl) test may detect whether stress –mental and physical – leads to an inadequate oxygen supply to the heart among people with coronary artery disease.

2017

  • FDA expands emergency use authorization for Abbott RealTime ZIKA molecular test beyond previous authorization to identify Zika using serum, plasma, and urine only.
  • Abbott Virus Hunters discover rare HIV-1 Group N, HBV AE, and HTLV-3 strains identified in Cameroon.

2018

  • Abbott announces its partnership with Y.R. Gaitonde Centre for AIDS Research and Education (YRGCARE) to study the country’s viral diversity to improve accuracy of diagnostic tests. Abbott provided study protocol and diagnostic equipment and YRGCARE helped with screening and sequencing rich patient data from infected populations in India.
  • Abbott receives CE Mark for its High Sensitive Troponin-I blood test for distribution in Europe. It is the first troponin test with CE Mark that can more accurately predict the chances of a heart attack or other cardiac event in adults who otherwise appear healthy.

2019

  • Abbott announces a team of its scientists identified a new subtype of the human immunodeficiency virus (HIV), called HIV-1 Group M, subtype L.

2020

  • Abbott receives FDA Emergency Use Authorization for COVID-19 antibody blood test on Alinity™ i system.
  • Abbott receives FDA Emergency Use Authorization for COVID-19 molecular test on new Alinity™ m system.
  • Abbott launches COVID-19 IgG antibody test for the ARCHITECT® i1000SR and i2000SR and Alinity i laboratory instruments.
  • Abbott receives FDA Emergency Use Authorization for its COVID-19 IgM antibody blood test.
  • Abbott receives CE Mark for its COVID-19 IgG quantitative antibody blood test.

2021

  • Abbott received FDA 510(K) clearance for the first rapid handheld blood test for concussions.
  • Abbott announces its Pandemic Defense Coalition: a global network of expert collaborators designed to help prevent future pandemics, currently searching for COVID-19 variants.
  • Abbott receives FDA Emergency Use Authorization for its COVID-19 IgG semi-quantitative antibody blood test.
  • Abbott receives FDA Emergency Use Authorization for laboratory PCR assay that detects and differentiates SARS-CoV-2, flu a, flu b and RSV in one test - and FDA EUA for asymptomatic usage of Alinity m COVID-19 test.

 


Explore


knowledge-center-learning-guide_200x300.jpg

Learning Guide

Build key laboratory competencies and explore topics from various disciplines with our learning guides.

Visit the Learning guides 

knowledge-center-crosslink_300x200.jpg

Knowledge Center

Find the latest information in laboratory science, therapeutic areas and Abbott innovation.

Visit the Knowledge Center

Press-Releases_300x200

Press Releases

Access press releases and special feature articles related to Abbott's latest innovations in diagnostics.

View press releases

REFERENCES

  1. Abbott Global Newsroom, 2021
  2. Abbott Internal Data

You are about to exit the Abbott family of websites for a 3rd party website

Links which take you out of Abbott worldwide websites are not under the control of Abbott, and Abbott is not responsible for the contents of any such site or any further links from such site. Abbott is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott. The website that you have requested also may not be optimised for your screen size.

Do you wish to continue and exit this website?

Yes No

You are about to enter an Abbott country or region specific website.

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions.

Do you wish to continue and enter this website?

Yes No

DO YOU WISH TO CONTINUE AND EXIT THE CORE LABORATORY WEBSITE?

Content is not under the control of corelaboratory.abbott.

Yes No